Clinical trials in Europe sometimes need to be conducted in exceptional contexts, particularly during public health emergencies such as pandemics or major health crises. In this context, the European Medicines Agency (EMA) has recently published new guidance on the conduct of clinical trials in Europe when normal research conditions are disrupted.
This guidance aims to help sponsors, investigators, and competent authorities maintain the continuity of clinical trials in Europe while ensuring participant safety and the reliability of scientific data.
The experience of the COVID-19 pandemic demonstrated that clinical trials in Europe may face major operational challenges: limited access to hospitals, difficulties in patient follow-up, and logistical disruptions. The new recommendations aim to anticipate such situations and ensure that clinical trials in Europe can continue despite these constraints.
Clinical Trials in Europe: Adapting Study Conduct During Public Health Emergencies
Clinical trials in Europe must be able to continue even when healthcare systems are under significant pressure. The new EMA guidance proposes several measures to adapt the conduct of clinical trials in Europe during emergency situations.
Among the main recommendations:
- adapting participant follow-up procedures
- increasing the use of remote visits when possible
- adjusting monitoring procedures
- managing protocol deviations flexibly when unavoidable
The objective is to ensure the continuity of clinical trials in Europe while maintaining a high level of participant protection.
https://health.ec.europa.eu/medicinal-products/clinical-trials_en
As the European regulatory framework recalls, a clinical trial can only be conducted if the safety and rights of participants are fully protected and if the study is designed to generate reliable scientific data. These principles remain fundamental for clinical trials in Europe, even in emergency situations.
Anticipating Health Crises in the Organization of Clinical Trials in Europe
One of the major lessons learned from the COVID-19 pandemic was the need to integrate health crisis management into the planning of clinical trials in Europe.
EMA recommendations therefore encourage sponsors conducting clinical trials in Europe to:
- develop risk-management plans in case of public health emergencies
- identify critical procedures that may need to be adapted
- document protocol deviations related to the crisis
- maintain close communication with regulatory authorities
This approach helps prevent sudden interruptions of clinical trials in Europe and preserves the scientific value of the data collected.
Clinical Trials in Europe and the Example of COVID-19 Vaccines
The COVID-19 pandemic is perhaps the most striking example of the ability of research systems to rapidly adapt clinical trials in Europe during a public health emergency.
The first COVID-19 vaccines were developed and authorized in less than one year, whereas vaccine development typically takes 10 to 15 years.
For example, the Comirnaty vaccine (BioNTech-Pfizer) received a conditional marketing authorization in the European Union in December 2020, less than twelve months after the virus was identified.
https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty
This unprecedented acceleration in clinical trials in Europe was not due to relaxed scientific standards but to several key factors:
- global mobilization of researchers and massive public funding
- parallel development of certain research phases
- the use of previously studied vaccine technologies, such as mRNA
- continuous regulatory evaluation procedures known as rolling reviews
These approaches allowed clinical trials in Europe to progress much faster without compromising scientific rigor or participant safety.
Clinical Trials in Europe: A Strategic Issue for European Biomedical Research
Clinical trials in Europe represent a central pillar of biomedical innovation. The ability of the European research system to maintain the continuity of clinical trials in Europe, even during public health crises, is therefore a strategic issue.
By clarifying best practices for emergency situations, the new EMA guidance strengthens the resilience of the European clinical trials ecosystem.
It also highlights the importance of close cooperation between sponsors, investigational sites, and health authorities to ensure patient protection while continuing the development of innovative therapies.
https://www.ema.europa.eu/en/human-regulatory-overview/research-development
